DaVita Inc., Denver, CO, USA.
Louisiana State University School of Medicine, New Orleans, LA, USA.
J Nephrol. 2023 Sep;36(7):1897-1905. doi: 10.1007/s40620-023-01703-y. Epub 2023 Aug 29.
Incremental peritoneal dialysis (PD) can be defined as a PD prescription that is less than the standard, full dose prescription and is typically used for patients initiating PD with residual kidney function. It has been suggested that use of incremental peritoneal dialysis may help preserve residual kidney function and may offer better quality of life due to the lower treatment burden, however published evidence is limited. In this study we assessed the associations between incremental peritoneal dialysis use and both clinical outcomes and quality of life measures in a large cohort of incident peritoneal dialysis patients in the US.
We considered adult patients initiating peritoneal dialysis between 31 July, 2015 and 31 May, 2019 within a single dialysis organization. Patients with body weight < 40 kg, amputation, or an estimated glomerular filtration rate > 20 mL/min during the first 4 weeks on peritoneal dialysis were excluded. Patients were assigned to exposure groups based on peritoneal dialysis prescription during dialysis weeks 5-8. Incremental peritoneal dialysis was defined by treatment frequency, number of exchanges/day, and exchange volume (for continuous ambulatory peritoneal dialysis patients) or by treatment frequency and presence/absence of last fill (for automated peritoneal dialysis patients). Analyses were performed separately for continuous ambulatory peritoneal dialysis and automated peritoneal dialysis. For each analysis, incremental peritoneal dialysis patients were propensity score matched to eligible full-dose peritoneal dialysis patients. Patients were followed for a maximum of 12 months until censoring for loss to follow-up or study end. Outcomes were compared using Poisson models (mortality, hospitalization, peritoneal dialysis discontinuation), linear mixed models (estimated glomerular filtration rate), and paired t tests (KDQOL domain scores).
Among continuous ambulatory peritoneal dialysis patients, compared to full-dose peritoneal dialysis, incremental peritoneal dialysis use was associated with better KDQOL scores on 3 domains: physical composite score (42.5 vs 37.7, p = 0.03), burden of kidney disease (60.2 vs 45.6, p = 0.003), effects of kidney disease (79.4 vs 72.3, p = 0.05). Hospitalization and mortality rates were numerically lower (0.77 vs 1.12 admits/pt-year, p = 0.09 and 5.0 vs 10.2 deaths/100 pt-years, p = 0.22), while no associations were found with estimated glomerular filtration rate or peritoneal dialysis discontinuation rate. Use of incremental peritoneal dialysis was not associated with any discernable effects on outcomes in automated peritoneal dialysis patients.
These results suggest that there may be benefits of using incremental PD in the context of continuous ambulatory peritoneal dialysis, particularly with respect to quality of life as a prescription strategy when initiating peritoneal dialysis. While no significant benefits of incremental peritoneal dialysis were detected among patients initiating automated peritoneal dialysis, no detrimental effects of using incremental schedules were observed for either peritoneal dialysis type.
递增式腹膜透析(IPD)可定义为低于标准全剂量处方的腹膜透析方案,通常用于起始腹膜透析时仍保留部分肾功能的患者。有研究提示,使用递增式腹膜透析可能有助于保留残余肾功能,并由于治疗负担较低而提供更好的生活质量,然而现有证据有限。本研究评估了递增式腹膜透析的使用与美国单家透析机构中大量起始腹膜透析患者的临床结局和生活质量指标之间的关联。
我们纳入了在 2015 年 7 月 31 日至 2019 年 5 月 31 日期间,于单一透析机构起始腹膜透析的成年患者。排除体重<40kg、截肢或起始腹膜透析后 4 周内估计肾小球滤过率>20mL/min 的患者。根据起始腹膜透析后第 5-8 周的腹膜透析处方,将患者分配至暴露组。递增式腹膜透析通过治疗频率、每日交换次数和交换量(对于持续非卧床腹膜透析患者)或通过治疗频率和末次留腹的存在/缺失(对于自动化腹膜透析患者)来定义。分别对持续非卧床腹膜透析和自动化腹膜透析进行分析。对于每项分析,递增式腹膜透析患者与符合条件的全剂量腹膜透析患者进行倾向评分匹配。患者最长随访 12 个月,直至失访或研究结束。使用泊松模型(死亡率、住院、腹膜透析终止)、线性混合模型(估计肾小球滤过率)和配对 t 检验(KDQOL 域评分)比较结局。
在持续非卧床腹膜透析患者中,与全剂量腹膜透析相比,递增式腹膜透析的使用与以下 3 个 KDQOL 域的评分改善相关:生理综合评分(42.5 比 37.7,p=0.03)、肾脏疾病负担评分(60.2 比 45.6,p=0.003)和肾脏疾病影响评分(79.4 比 72.3,p=0.05)。住院率和死亡率呈数值降低趋势(0.77 比 1.12 次/患者年,p=0.09 和 5.0 比 10.2 次/100 患者年,p=0.22),但与估计肾小球滤过率或腹膜透析终止率无关。递增式腹膜透析在自动化腹膜透析患者中未显示出任何可识别的结局获益。
这些结果提示,递增式腹膜透析可能对持续非卧床腹膜透析有益,尤其是在起始腹膜透析时作为处方策略,可改善生活质量。虽然在起始自动化腹膜透析的患者中未检测到递增式腹膜透析的显著获益,但在两种腹膜透析类型中均未观察到递增式方案的有害影响。